Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$79.24M, compared with -$26.14M a year earlier. Trailing-twelve-month net income was -$250.64M.

Context

  • Net income amounted to 1316.9% of revenue in FY2025.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 12 analysts of -$243.23M (-23.1%) for the fiscal year ending Dec 2026, a slowdown from the +16.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$79.24M-19.8% QoQ
Last fiscal yearDec 2025
-$197.53M+16.2% YoY
LTMMar 2026
-$250.64M-12.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-203.2%-18.4%+184.8 pp
1 year+16.2%-23.1%-39.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(197.53M) USD
Year-over-year change
+16.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.0% is the 4th highest of 10, against a peer median of -25.8%.
CNTA Competitors
Net Income for CNTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026-$215K USD+99.9%—0.0%
ZLABZai Lab LimitedLTM Jun 2026-$188.21M USD+11.4%—41.9%
CELCCelcuity Inc.LTM Jun 2026-$226.48M USD-52.3%——
CGONCG Oncology, Inc. Common stockLTM Sep 2026-$237.46M USD-56.8%—3851.1%
CNTACentessa Pharmaceuticals plcLTM Mar 2026-$250.64M USD-12.0%——
APGEApogee Therapeutics, Inc.LTM Jun 2026-$294.37M USD-23.9%——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$428.73M USD-40.0%——
DYNDyne Therapeutics, Inc.LTM Jun 2026-$519.41M USD-25.8%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$609.36M USD-10.9%—91.0%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.21B CNY-198.2%—216.5%
Peer median (excluding CNTA) —-25.8%—91.0%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.